Skip to main content

Apex Infusion partners with SkyNight Capital as it seeks market expansion

City: San Francisco, CA
Buyer: SkyKnight Capital
Seller: Apex Infusion
Date / Year: July 27, 2026
Sector: Infusion Therapy
Keywords: SkyKnight Capital, Apex Infusion, Infusion Therapy, Moussie Haile, Rick Smith

SAN FRANCISCO – Apex Infusion, an omnichannel infusion services provider, has entered into a definitive agreement to partner with SkyKnight Capital, a private equity firm, to drive the company’s next chapter of growth.

Apex’s clinician-led management team will retain a significant ownership stake and continue to lead the business. FFL Partners will also remain a minority investor in the company.

“Apex has reached an exciting milestone,” said Rick Smith, executive chairman and co-founder of Apex. “We have built a differentiated platform, established strong relationships across the health care ecosystem, and proven that our model can scale rapidly. With SkyKnight and FFL, we are well positioned to accelerate our expansion and extend Apex’s model of care to more patients nationwide.”

Founded in 2006 and headquartered in Signal Hill, Calif., Apex serves patients through an expansive network of home infusion nurses and approximately 40 ambulatory infusion suite locations.

Apex says SkyKnight will support the company as it evaluates opportunities for new market expansion, strategic partnerships with leading health systems and payers, and technology-enabled initiatives designed to enhance patient access.

“What our team has built at Apex is something special – a best-in-class infusion platform designed to optimize the patient experience at every step,” said Moussie Haile, PharmD, CEO and co-founder of Apex. “By delivering therapy in a comfortable clinical setting or the familiarity of home, we give patients better outcomes, greater dignity and a real improvement in their quality of life. As we enter this next chapter, our priority remains unchanged: to preserve the clinical culture that defines Apex while bringing our high standard of care to more patients and communities.”

The partnership is subject to customary closing conditions, including the receipt of required regulatory approvals.

The M&A market for healthcare companies continues to build on STRATEGIC opportunities and a fragmented market. Consolidations along with unprecedented demand are driving scale across the continuum of care. The strategic corporate buyers and private equity investors remain committed to acquiring strong businesses that are well prepared for a transaction. Across the continuum of care, these buyers and investors are looking for well established, profitable businesses and offering prime valuations and options for management.

Do you know the current market value of your business? We do! We are here to help you plan, prepare, explore and succeed in executing your strategic options.

Contact Paragon Ventures for more information.  

www.paragonventures.com

800-719-1555

OneroRx Inc. Completes Acquisition of NuCara Pharmacy Locations
Quad-C Managment Announces Investment in Dane Street